Medicine & Pharmaceuticals - Wandtv.com, NewsCenter17, StormCenter17, Central Illinois News-

Latest News Releases

*DISCLAIMER*: Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

Medicine & Pharmaceuticals News Releases via PRNewswireMore>>
Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany
Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany
The potential of the pulmonary route as a non-invasive administration for systemic delivery of therapeutic agents has been receiving undeniable attention with the recent advances of the inhalation drug delivery showing...More >>
The potential of the pulmonary route as a non-invasive administration for systemic delivery of therapeutic agents has been receiving undeniable attention with the recent advances of the inhalation drug delivery showing...More >>
Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
More than half of women diagnosed with early stage breast cancer may not benefit from chemotherapy and still have excellent outcomes. To educate women, Agendia, Inc. has announced the launch of one of the largest sources of...More >>
More than half of women diagnosed with early stage breast cancer may not benefit from chemotherapy and still have excellent outcomes. To educate women, Agendia, Inc. has announced the launch of one of the largest sources of...More >>
Zensun Announces Positive Clinical Results for Neucardin™ to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients
Zensun Announces Positive Clinical Results for Neucardin™ to Improve Heart Function and Reduce Mortality in Chronic Heart Failure Patients
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies...More >>
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies...More >>
Positive Animal Data Presented at EuroPCR Sets Stage for Advancing Neovasc's Tiara(TM) Transcatheter Mitral Valve into Human Trials
Positive Animal Data Presented at EuroPCR Sets Stage for Advancing Neovasc's Tiara(TM) Transcatheter Mitral Valve into Human Trials
-Longer-Term Animal Data Suggests Tiara Device for the Transcatheter Treatment of Mitral Valve Disease Appears Safe and Well ToleratedMore >>
-Longer-Term Animal Data Suggests Tiara Device for the Transcatheter Treatment of Mitral Valve Disease Appears Safe and Well ToleratedMore >>
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824...More >>
Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration (FDA). OMS824...More >>
InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating...More >>
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating...More >>
Prometheus Laboratories Presents New Data On Growing IBD Diagnostic Portfolio At Digestive Disease Week 2013
Prometheus Laboratories Presents New Data On Growing IBD Diagnostic Portfolio At Digestive Disease Week 2013
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the eighteen abstracts relating to its proprietary diagnostic platform were presented at Digestive Disease Week (DDW) 2013.More >>
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the eighteen abstracts relating to its proprietary diagnostic platform were presented at Digestive Disease Week (DDW) 2013.More >>
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NasdaqGS: AMAG -News). The...More >>
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NasdaqGS: AMAG -News). The...More >>
Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services
Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services
Z-Medica, a leading developer and marketer of hemostatic agents, announced today it has launched the first-ever line of products designed to meet the unique needs of Emergency Medical Services. The line includes QuikClot®...More >>
Z-Medica, a leading developer and marketer of hemostatic agents, announced today it has launched the first-ever line of products designed to meet the unique needs of Emergency Medical Services. The line includes QuikClot®...More >>
Executive Leadership Team Brings Decades of Entrepreneurial, Manufacturing and Innovation Success to Biozoom
Executive Leadership Team Brings Decades of Entrepreneurial, Manufacturing and Innovation Success to Biozoom
Biozoom has created the world's first portable, handheld consumer device to use reflection spectroscopy for real-time diagnostics in humans. A technological breakthrough that some describe as a disruptive technology for...More >>
Biozoom (OTCBB: BIZM) has created the world's first portable, handheld consumer device to use reflection spectroscopy for real-time diagnostics in humans. A technological breakthrough that some describe as a disruptive...More >>
MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
MGT Capital Investments, Inc. (NYSE MKT: MGT) announced today that the Company will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. Robert...More >>
MGT Capital Investments, Inc. (NYSE MKT: MGT) announced today that the Company will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. Robert...More >>
Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C (Alpha1-Proteinase Inhibitor [Human]) increased levels of the alpha1 protein in...More >>
Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C (Alpha1-Proteinase Inhibitor [Human]) increased levels of the alpha1 protein in...More >>
Carnegie Mellon Invites Brad Pitt To Campus For Face Blindness Diagnosis, Research
Carnegie Mellon Invites Brad Pitt To Campus For Face Blindness Diagnosis, Research
In light of Brad Pitt's recent announcement attributing his poor memory to prosopagnosia, or face blindness, Carnegie Mellon University extends an invitation to the actor to have his brain imaged and examined by renowned...More >>
In light of Brad Pitt's recent announcement attributing his poor memory to prosopagnosia, or face blindness, Carnegie Mellon University extends an invitation to the actor to have his brain imaged and examined by renowned...More >>
Syneron Reports First Quarter 2013 Results
Syneron Reports First Quarter 2013 Results
Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, today announced financial results for the three month period ended March 31, 2013.More >>
Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, today announced financial results for the three month period ended March 31, 2013.More >>
Lifestyle Designer Kathy Ireland & Noted Surgeon and Researcher, Dr. David Scharp To Launch Skin Rejuvenation Product, Stemage, From Stem Cell-Derived Ingredients
Lifestyle Designer Kathy Ireland & Noted Surgeon and Researcher, Dr. David Scharp To Launch Skin Rejuvenation Product, Stemage, From Stem Cell-Derived Ingredients
Kathy Ireland, CEO and Chief Designer of kathy ireland Worldwide (kiWW) and leading women's health advocate, and world-renowned board certified surgeon Dr. David Scharp today announced their collaboration in bringing to...More >>
Kathy Ireland, CEO and Chief Designer of kathy ireland Worldwide (kiWW) and leading women's health advocate, and world-renowned board certified surgeon Dr. David Scharp today announced their collaboration in bringing to...More >>
Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court
Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court
Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today, further to the Company's announcement dated May 9, 2013 that it had filed a motion with the Tel Aviv District Court (the "Court") to...More >>
Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today, further to the Company's announcement dated May 9, 2013 that it had filed a motion with the Tel Aviv District Court (the "Court") to...More >>
Patheon Announces Changes to its Commercial Operations Structure
Patheon Announces Changes to its Commercial Operations Structure
TORONTO, May 21, 2013 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, announced today that Antonella Mancuso,...More >>
TORONTO, May 21, 2013 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, announced today that Antonella Mancuso,...More >>
ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials
ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials
The congress of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. Nearly 10,000 participants are in...More >>
The congress of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) is the biggest congress in Europe on nephrology and renal replacement therapy. Nearly 10,000 participants are in...More >>
Canadians seek allergy relief only when symptoms become unbearable
Canadians seek allergy relief only when symptoms become unbearable
MONTREAL, May 21, 2013 /CNW Telbec/ - A national survey conducted by Léger Marketing highlights that one quarter of Canadians who suffer from allergies will wait until their symptoms become unbearable before seeking...More >>
MONTREAL, May 21, 2013 /CNW Telbec/ - A national survey conducted by Léger Marketing highlights that one quarter of Canadians who suffer from allergies will wait until their symptoms become unbearable before seeking...More >>
Lehigh Valley Expands Fleet of Superbug-Slaying Robots
Lehigh Valley Expands Fleet of Superbug-Slaying Robots
Lehigh Valley Health Network has announced the deployment of two additional TRU-D SmartUVCTM devices, adding to its existing arsenal of five 5-foot-5 germ-killing UV disinfection robots. With seven devices taking up...More >>
Lehigh Valley Health Network has announced the deployment of two additional TRU-D SmartUVCTM devices, adding to its existing arsenal of five 5-foot-5 germ-killing UV disinfection robots. With seven devices taking up...More >>
uniQure and Consortium to Receive EUR 2.5 Million Eurostars Grant to Develop RNAi Gene Therapy for Huntington's Disease
uniQure and Consortium to Receive EUR 2.5 Million Eurostars Grant to Develop RNAi Gene Therapy for Huntington's Disease
uniQure B.V., a leader in the field of human gene therapy, today announced that with its consortium partners it is to receive a EUR 2.5 million Eurostars grant to develop an RNA interference (RNAi) gene therapy for...More >>
uniQure B.V., a leader in the field of human gene therapy, today announced that with its consortium partners it is to receive a EUR 2.5 million Eurostars grant to develop an RNA interference (RNAi) gene therapy for...More >>
BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb, its President...More >>
BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb, its President...More >>
U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015
U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015
U.S. spending on specialty prescription drugs - those used to treat chronic, complex diseases such as cancer, multiple sclerosis and rheumatoid arthritis - is projected to increase 67 percent by the end of 2015, according to...More >>
U.S. spending on specialty prescription drugs - those used to treat chronic, complex diseases such as cancer, multiple sclerosis and rheumatoid arthritis - is projected to increase 67 percent by the end of 2015, according to...More >>
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the...More >>
Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the...More >>
Echo Therapeutics Announces Institutional Review Board (IRB) Approval for Its Clinical Trial of the Symphony® CGM System
Echo Therapeutics Announces Institutional Review Board (IRB) Approval for Its Clinical Trial of the Symphony® CGM System
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical...More >>
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical...More >>
Delayed Healing of Coronary Artery Following Implantation of Drug Eluting Stents, Increasing Risk of Thrombosis, is a Top Concern of Interventional Cardiologists, International Survey Shows
Delayed Healing of Coronary Artery Following Implantation of Drug Eluting Stents, Increasing Risk of Thrombosis, is a Top Concern of Interventional Cardiologists, International Survey Shows
The delayed healing of the coronary artery following physicians' use of drug eluting stents (DES), which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists,...More >>
The delayed healing of the coronary artery following physicians' use of drug eluting stents (DES), which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists,...More >>
AmeriCares Disaster Response Team Headed to Oklahoma
AmeriCares Disaster Response Team Headed to Oklahoma
AmeriCares is deploying an emergency response team to Oklahoma City to coordinate deliveries of relief supplies and medical aid for tornado survivors. The aid organization has reached out to health clinics, food banks and...More >>
AmeriCares is deploying an emergency response team to Oklahoma City to coordinate deliveries of relief supplies and medical aid for tornado survivors. The aid organization has reached out to health clinics, food banks and...More >>
Patheon Announces Date of Fiscal 2013 Second Quarter Financial Results
Patheon Announces Date of Fiscal 2013 Second Quarter Financial Results
TORONTO, May 20, 2013 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, announced today that it will report its...More >>
TORONTO, May 20, 2013 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, announced today that it will report its...More >>
TRACE Releases 2012 Global Enforcement Report
TRACE Releases 2012 Global Enforcement Report
TRACE International today released its Global Enforcement Report (GER) 2012, finding that prosecutions against individuals and government or business entities for bribery and corruption trended downward last year. The GER...More >>
TRACE International today released its Global Enforcement Report (GER) 2012, finding that prosecutions against individuals and government or business entities for bribery and corruption trended downward last year. The GER...More >>
Asmacure Highlights Four Presentations on Novel Pulmonary Development Compound ASM-024 Presented at American Thoracic Society 2013 International Conference
Asmacure Highlights Four Presentations on Novel Pulmonary Development Compound ASM-024 Presented at American Thoracic Society 2013 International Conference
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of...More >>
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of...More >>
Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference
Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies announced today that Dr. Peter Suzdak, CEO of Rexahn, will present at the Second...More >>
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies announced today that Dr. Peter Suzdak, CEO of Rexahn, will present at the Second...More >>
CytoSorbents To Present At The Second Annual Marcum LLP MicroCap Conference
CytoSorbents To Present At The Second Annual Marcum LLP MicroCap Conference
CytoSorbents Corporation (CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, announced today that Dr. Phillip Chan, Chief Executive Officer, will present...More >>
CytoSorbents Corporation (CTSO), a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses, announced today that Dr. Phillip Chan, Chief Executive Officer, will present...More >>
BioRestorative Therapies Signs Agreement with Dexterity, Inc. to Advance Production of the Company's Novel brtxDISC™ Stem Cell Therapy Device
BioRestorative Therapies Signs Agreement with Dexterity, Inc. to Advance Production of the Company's Novel brtxDISC™ Stem Cell Therapy Device
BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting...More >>
BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announces the signing of a consulting...More >>
From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
The many health care providers working at Eli Lilly and Company (NYSE:LLY) - including doctors, nurses, and pharmacists - play a vital role in bringing new and innovative medicines to patients. From research labs to...More >>
The many health care providers working at Eli Lilly and Company (NYSE:LLY) - including doctors, nurses, and pharmacists - play a vital role in bringing new and innovative medicines to patients. From research labs to...More >>
Pistachios: All They're Cracked Up To Be
Pistachios: All They're Cracked Up To Be
A new research study, using an experimental model that mimics digestion, suggests that nearly all of the polyphenols in pistachios are released to the body during digestion. The new findings, when considered along with...More >>
A new research study, using an experimental model that mimics digestion, suggests that nearly all of the polyphenols in pistachios are released to the body during digestion. The new findings, when considered along with...More >>
Value Edge launches Pharma Analytics Blog, Pharma Musings
Value Edge launches Pharma Analytics Blog, Pharma Musings
Pharma Musings will be a world class Pharma analytics and research blog with thoughtful insights Value Edge, the leading Bio-Pharma focused outsourcing research and analytics provider today announced the launch of its blog,...More >>
Pharma Musings will be a world class Pharma analytics and research blog with thoughtful insights Value Edge, the leading Bio-Pharma focused outsourcing research and analytics provider today announced the launch of its blog,...More >>
Elsevier and Russian Ministry of Education and Science Announce 2013 Scopus Award Winners
Elsevier and Russian Ministry of Education and Science Announce 2013 Scopus Award Winners
Elsevier, the world-leading provider of scientific, technical, and medical information products and services, and the Russian Ministry of Education and Science announced the winners of the 2013 Scopus Awards Russia. The...More >>
Elsevier, the world-leading provider of scientific, technical, and medical information products and services, and the Russian Ministry of Education and Science announced the winners of the 2013 Scopus Awards Russia. The...More >>
Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to Improve Tacrolimus-Induced Tremors
Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to Improve Tacrolimus-Induced Tremors
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney transplant patients. The study,...More >>
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney transplant patients. The study,...More >>
German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)
German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for PIXUVRI® (pixantrone), which is indicated as a...More >>
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for PIXUVRI® (pixantrone), which is indicated as a...More >>
Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder
Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of...More >>
Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of...More >>
Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that...More >>
Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that...More >>
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups. The primary...More >>
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups. The primary...More >>
Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion
Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion
As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and...More >>
As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and...More >>
Collegium Pharmaceutical's CEO to Present at the UBS Global Health Care Conference in New York on May 20, 2013
Collegium Pharmaceutical's CEO to Present at the UBS Global Health Care Conference in New York on May 20, 2013
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at...More >>
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at...More >>
Eisai Highlights New Research On Melanoma, Breast and Endometrial Cancer at ASCO Annual Meeting
Eisai Highlights New Research On Melanoma, Breast and Endometrial Cancer at ASCO Annual Meeting
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO),...More >>
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO),...More >>
Nevada Donor Network Announces Unprecedented Growth In Organ & Tissue Donation
Nevada Donor Network Announces Unprecedented Growth In Organ & Tissue Donation
Nevada Donor Network is proud to announce record breaking increases in all aspects of organ and tissue donation. Our staff facilitated donations from 75 organ donors, 296 tissue donors and 546 cornea donors during 2012. The...More >>
Nevada Donor Network is proud to announce record breaking increases in all aspects of organ and tissue donation. Our staff facilitated donations from 75 organ donors, 296 tissue donors and 546 cornea donors during 2012. The...More >>
ThromboGenics Business Update
ThromboGenics Business Update
JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA® in wet AMD patients shows 24% VMA resolution rate for JETREA® treated...More >>
JETREA® gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA® in wet AMD patients shows 24% VMA resolution rate for JETREA® treated...More >>
New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy
New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy
A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of what causes this progressive and chronic condition, or are simply dissatisfied with...More >>
A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of what causes this progressive and chronic condition, or are simply dissatisfied with...More >>
Growing Opportunities in the Construction, Pharma and E-learning Sectors in India
Growing Opportunities in the Construction, Pharma and E-learning Sectors in India
The construction sector in India The construction industry in India is the second largest in the country, after agriculture. It has been an integral part of the Indian economy and has been consistently contributing around...More >>
The construction sector in India The construction industry in India is the second largest in the country, after agriculture. It has been an integral part of the Indian economy and has been consistently contributing around...More >>
Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the publication in the journal Analytical Chemistry of a study by a team of scientists led by Dr. Bruce Kristal, Associate Professor of...More >>
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the publication in the journal Analytical Chemistry of a study by a team of scientists led by Dr. Bruce Kristal, Associate Professor of...More >>
Syneron Introduces Enhancements to its Innovative Body Shaping Products
Syneron Introduces Enhancements to its Innovative Body Shaping Products
Expands treatment capabilities, reduces treatment time, and improves overall experience with UltraShape and VelaShape systems Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, announced today...More >>
Expands treatment capabilities, reduces treatment time, and improves overall experience with UltraShape and VelaShape systems Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, announced today...More >>
Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company...More >>
Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company...More >>
Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
Professional football icon Jerome Bettis and Sanofi US, the makers of Auvi-Q™ (epinephrine injection, USP), have teamed up to raise awareness about severe allergic reactions (anaphylaxis) and introduce The Severe Allergy...More >>
Professional football icon Jerome Bettis and Sanofi US, the makers of Auvi-Q™ (epinephrine injection, USP), have teamed up to raise awareness about severe allergic reactions (anaphylaxis) and introduce The Severe Allergy...More >>
DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting
DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting
New findings validate clinical utility in Colorectal Cancer StagingMore >>
New findings validate clinical utility in Colorectal Cancer StagingMore >>
Echo Therapeutics to Unveil Symphony® CGM System in Webcast
Echo Therapeutics to Unveil Symphony® CGM System in Webcast
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the unveiling and demonstration...More >>
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the unveiling and demonstration...More >>
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as...More >>
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as...More >>
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual...More >>
AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual...More >>
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug...More >>
Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug...More >>
Mathew Whelan Joins Remedi SeniorCare® as Vice President and Corporate Controller
Mathew Whelan Joins Remedi SeniorCare® as Vice President and Corporate Controller
Remedi SeniorCare® has named Mathew Whelan as Vice President and Corporate Controller. With over 20 years of experience building and leading accounting teams, Matt will serve as a key member of the corporate financial team...More >>
Remedi SeniorCare® has named Mathew Whelan as Vice President and Corporate Controller. With over 20 years of experience building and leading accounting teams, Matt will serve as a key member of the corporate financial team...More >>
Life After Failing TVM Treatments is a Rollercoaster of Side Effects for Women
Life After Failing TVM Treatments is a Rollercoaster of Side Effects for Women
Imagine what it would feel like to have a cheese grater wearing at your tissue every time you moved. For women with transvaginal mesh (TVM) implants this stomach wrenching analogy can hit home all too closely. Complications...More >>
Imagine what it would feel like to have a cheese grater wearing at your tissue every time you moved. For women with transvaginal mesh (TVM) implants this stomach wrenching analogy can hit home all too closely. Complications...More >>
Veloxis Pharmaceuticals announces financial results for the first three months of 2013
Veloxis Pharmaceuticals announces financial results for the first three months of 2013
Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T
Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-T
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a...More >>
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a...More >>
International Isotopes Inc. Announces First Quarter 2013 Financial Results
International Isotopes Inc. Announces First Quarter 2013 Financial Results
International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the first quarter ended March 31, 2013.More >>
International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the first quarter ended March 31, 2013.More >>
New Web Radio Show "Alzheimer's Answers" Gives Callers Live Access to Alzheimer's Disease Expert Dr. William Van Horn
New Web Radio Show "Alzheimer's Answers" Gives Callers Live Access to Alzheimer's Disease Expert Dr. William Van Horn
Dr. William Van Horn, a recognized expert in the prevention and treatment of Alzheimer's disease, is now hosting a web radio show to share his unique experiences with listeners and answer callers' questions. The...More >>
Dr. William Van Horn, a recognized expert in the prevention and treatment of Alzheimer's disease, is now hosting a web radio show to share his unique experiences with listeners and answer callers' questions. The...More >>
Peregrine Health Services Selects COMS Interactive
Peregrine Health Services Selects COMS Interactive
Peregrine Health Services, Inc. (Peregrine), is a well-respected Midwest long-term care organization, that is deploying Daylight IQ™, the COMS Interactive (Clinical Outcomes Management System or COMS) product suite, as a key...More >>
Peregrine Health Services, Inc. (Peregrine), is a well-respected Midwest long-term care organization, that is deploying Daylight IQ™, the COMS Interactive (Clinical Outcomes Management System or COMS) product suite, as a key...More >>
Mast Therapeutics Reports First Quarter 2013 Financial Results
Mast Therapeutics Reports First Quarter 2013 Financial Results
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013.More >>
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013.More >>
New Published Clinical Study Shows Masimo PVI® Helps Clinicians Assess Fluid Responsiveness in Pediatric Patients
New Published Clinical Study Shows Masimo PVI® Helps Clinicians Assess Fluid Responsiveness in Pediatric Patients
Masimo (NASDAQ: MASI) announced today a new study in the British Journal of Anesthesia demonstrates that Masimo's noninvasive PVI® can be used to help clinicians accurately assess fluid responsiveness in mechanically...More >>
Masimo (NASDAQ: MASI) announced today a new study in the British Journal of Anesthesia demonstrates that Masimo's noninvasive PVI® can be used to help clinicians accurately assess fluid responsiveness in mechanically...More >>
VirtualScopics Reports First Quarter 2013 Results
VirtualScopics Reports First Quarter 2013 Results
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging, today announced revenues of $2,532,587 for the quarter ended March 31, 2013 compared to $3,702,159 for the quarter ended March 31, 2012. Net...More >>
VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging, today announced revenues of $2,532,587 for the quarter ended March 31, 2013 compared to $3,702,159 for the quarter ended March 31, 2012. Net...More >>
Personalized Medicine Market Analysis
Personalized Medicine Market Analysis
Reportlinker.com announces that a new market research report is available in its catalogue:More >>
Reportlinker.com announces that a new market research report is available in its catalogue:More >>
Nuvo Research granted U.S. Patent for treatment of allergic rhinitis and allergic asthma with WF10
Nuvo Research granted U.S. Patent for treatment of allergic rhinitis and allergic asthma with WF10
MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune...More >>
MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune...More >>
GenoVive, a pioneer in DNA-based weight management solutions, today announced the company's first European partnership as of May 1, 2013 with DNADIETA based in Poland.
GenoVive, a pioneer in DNA-based weight management solutions, today announced the company's first European partnership as of May 1, 2013 with DNADIETA based in Poland.
GenoVive is forming worldwide partnerships and is engaged in discussions with several countries in Europe and other continents to bring its "Weight Loss Designed by Science" program internationally. Vic Castellon, PhamD....More >>
GenoVive is forming worldwide partnerships and is engaged in discussions with several countries in Europe and other continents to bring its "Weight Loss Designed by Science" program internationally. Vic Castellon, PhamD....More >>
Craft Brewers Nationwide Join the ALS Therapy Development Institute in the 'Ales for ALS' Campaign to Battle Lou Gehrig's Disease
Craft Brewers Nationwide Join the ALS Therapy Development Institute in the 'Ales for ALS' Campaign to Battle Lou Gehrig's Disease
The ALS Therapy Development Institute (ALS TDI) announced today that 38 microbrewers across the country have joined the Ales for ALS campaign in support of ALS TDI's mission to discover and develop effective treatments...More >>
The ALS Therapy Development Institute (ALS TDI) announced today that 38 microbrewers across the country have joined the Ales for ALS campaign in support of ALS TDI's mission to discover and develop effective treatments...More >>
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers that have become resistant to standard treatments, announced today the publication in...More >>
Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers that have become resistant to standard treatments, announced today the publication in...More >>
Nutrastar Announces First Quarter 2013 Results, Maintains Full Year Revenue Guidance Range of $44 million to $46 Million
Nutrastar Announces First Quarter 2013 Results, Maintains Full Year Revenue Guidance Range of $44 million to $46 Million
Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional...More >>
Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional...More >>
TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg...More >>
TWi Pharmaceuticals, Inc. (Taiwan OTC: 4180) today announced that it has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride Extended Release Tablets 1mg, 2mg, 3mg and 4mg...More >>
Gluten-Free Products Market Worth $6,206.2 Million by 2018
Gluten-Free Products Market Worth $6,206.2 Million by 2018
The report "Gluten-Free Products Market By Type (Bakery & Confectionery, Snacks, Breakfast Cereals, Baking Mixes & Flour, Meat & Poultry Products), Sales Channel (Natural & Conventional) &...More >>
The report "Gluten-Free Products Market By Type (Bakery & Confectionery, Snacks, Breakfast Cereals, Baking Mixes & Flour, Meat & Poultry Products), Sales Channel (Natural & Conventional) &...More >>
Domestic Production of Medical Isotope Mo-99 Moves a Step Closer at Los Alamos
Domestic Production of Medical Isotope Mo-99 Moves a Step Closer at Los Alamos
Today, Los Alamos National Laboratory announced that for the first time, irradiated uranium fuel has been recycled and reused for molybdenum-99 (Mo-99) production, with virtually no losses in Mo-99 yields or uranium...More >>
Today, Los Alamos National Laboratory announced that for the first time, irradiated uranium fuel has been recycled and reused for molybdenum-99 (Mo-99) production, with virtually no losses in Mo-99 yields or uranium...More >>
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business
BELLEVILLE, ON, May 13, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has engaged U.S.-based Evercore...More >>
BELLEVILLE, ON, May 13, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has engaged U.S.-based Evercore...More >>
SPO Reports Results for First Quarter 2013
SPO Reports Results for First Quarter 2013
SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today financial results for the fiscal quarter ended March 31, 2013. Total revenue...More >>
SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today financial results for the fiscal quarter ended March 31, 2013. Total revenue...More >>
Assessing Your Asthma is Key to Taking Control
Assessing Your Asthma is Key to Taking Control
Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by...More >>
Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by...More >>
Thermic Fluid Market is Expected to Reach USD 2.78 Billion Globally by 2018: Transparency Market Research
Thermic Fluid Market is Expected to Reach USD 2.78 Billion Globally by 2018: Transparency Market Research
According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Thermic Fluid Market by Product (Silicone and Aromatics, Mineral Oils, GlycolBased Fluids, etc.), by...More >>
According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Thermic Fluid Market by Product (Silicone and Aromatics, Mineral Oils, GlycolBased Fluids, etc.), by...More >>
NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative
NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3...More >>
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3...More >>
Cardiome Reports First Quarter Results
Cardiome Reports First Quarter Results
Cardiome to conduct conference call and webcast today, May 13, at 4:15 p.m. Eastern (1:15 p.m. Pacific)More >>
Cardiome to conduct conference call and webcast today, May 13, at 4:15 p.m. Eastern (1:15 p.m. Pacific)More >>
New Clinical Studies Presented at the International Anesthesia Research Society Annual Meeting Show Benefits of Masimo Noninvasive Patient Monitoring Technologies: SpHb®, RRa™, and SedLine®
New Clinical Studies Presented at the International Anesthesia Research Society Annual Meeting Show Benefits of Masimo Noninvasive Patient Monitoring Technologies: SpHb®, RRa™, and SedLine®
Masimo (NASDAQ: MASI) announced today that three new clinical studies evaluating Masimo noninvasive patient monitoring technologies were presented before the world's leading anesthesia educators and investigators at the...More >>
Masimo (NASDAQ: MASI) announced today that three new clinical studies evaluating Masimo noninvasive patient monitoring technologies were presented before the world's leading anesthesia educators and investigators at the...More >>
Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone
Endo Health Solutions Responds to FDA's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone
Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA) has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals Inc. Endo presented FDA data collected...More >>
Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that the U.S. Food and Drug Administration (FDA) has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals Inc. Endo presented FDA data collected...More >>
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of...More >>
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of...More >>
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Bernstein Liebhard LLP today announced that a securities class action has been commenced in the United States District Court for the District of Massachusetts on behalf of a class (the "Class") of purchasers of Aveo...More >>
Bernstein Liebhard LLP today announced that a securities class action has been commenced in the United States District Court for the District of Massachusetts on behalf of a class (the "Class") of purchasers of Aveo...More >>
Echo Therapeutics Announces First Quarter 2013 Financial Results
Echo Therapeutics Announces First Quarter 2013 Financial Results
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the...More >>
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the...More >>
Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
Life Care Medical Devices Ltd (OTCBB:LCMD) today announced the opening of their European subsidiary offices in Dublin, Ireland. Life Care Medical Devices Ltd, Ireland will manage all aspects of the company's European...More >>
Life Care Medical Devices Ltd (OTCBB:LCMD) today announced the opening of their European subsidiary offices in Dublin, Ireland. Life Care Medical Devices Ltd, Ireland will manage all aspects of the company's European...More >>
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference
NASDAQ: CRME TSX: COMMore >>
NASDAQ: CRME TSX: COMMore >>
Concord Medical to Report First Quarter 2013 Financial Results on May 21, 2013
Concord Medical to Report First Quarter 2013 Financial Results on May 21, 2013
Conference call to discuss results will be held on May 22, 2013More >>
Conference call to discuss results will be held on May 22, 2013More >>
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline...More >>
Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline...More >>
ScinoPharm Taiwan and Coland Holdings Establish Strategic Alliance for Oncological Injectable Products for China
ScinoPharm Taiwan and Coland Holdings Establish Strategic Alliance for Oncological Injectable Products for China
ScinoPharm Taiwan Ltd. (TSE: 1789.TW) and Coland Holdings Ltd. (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several Active...More >>
ScinoPharm Taiwan Ltd. (TSE: 1789.TW) and Coland Holdings Ltd. (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several Active...More >>
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the...More >>
Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the...More >>
From "Wall-less Hospitals" to Skin-Embedded Chips: Predictions for the Future of Health Tech
From "Wall-less Hospitals" to Skin-Embedded Chips: Predictions for the Future of Health Tech
As part of its upcoming Health:Refactored conference, Health 2.0 wants to help elopers and designers envision the future of health tech -- a future wide open for them to create. This inaugural, first-of-a-kind conference is...More >>
As part of its upcoming Health:Refactored conference, Health 2.0 wants to help developers and designers envision the future of health tech -- a future wide open for them to create. This inaugural, first-of-a-kind conference...More >>
Infinity Group Signs Agreement in Hall of the People in Ceremony Attended by the Prime Ministers of Israel and China
Infinity Group Signs Agreement in Hall of the People in Ceremony Attended by the Prime Ministers of Israel and China
Infinity Group, a cross-border platform, announced today that it signed a memorandum of understanding with China this week in the Hall of the People in Beijing in the presence of Prime Minister of China Li Keqaing and Prime...More >>
Infinity Group, a cross-border platform, announced today that it signed a memorandum of understanding with China this week in the Hall of the People in Beijing in the presence of Prime Minister of China Li Keqaing and Prime...More >>
Former FDA Official Tim Cote Joins Emmaus Medical as Regulatory Advisor
Former FDA Official Tim Cote Joins Emmaus Medical as Regulatory Advisor
Timothy Cote, M.D., MPH, former director of the Office of Orphan Product Development of the U.S. Food and Drug Administration, has joined Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, in...More >>
Timothy Cote, M.D., MPH, former director of the Office of Orphan Product Development of the U.S. Food and Drug Administration, has joined Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, in...More >>
Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2%
Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2%
MISSISSAUGA, ON, May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European...More >>
MISSISSAUGA, ON, May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European...More >>
BioScrip Reports First Quarter 2013 Financial Results
BioScrip Reports First Quarter 2013 Financial Results
BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 first quarter financial results. First quarter revenue from continuing operations was $199.1 million and the net loss from continuing operations was $7.5 million, or $0.13...More >>
BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 first quarter financial results. First quarter revenue from continuing operations was $199.1 million and the net loss from continuing operations was $7.5 million, or $0.13...More >>
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results
(all figures are in Canadian dollars unless otherwise noted)More >>
(all figures are in Canadian dollars unless otherwise noted)More >>

News Releases via PR NewswireNews Releases via PR NewswireMore>>
Entertainment News Releases via PRNewswire
Entertainment
Entertainment News Releases via PRNewswire
Travel
Travel News Releases via PRNewswire
Political Campaigns
Political Campaigns News Releases via PRNewswire
Medicine & Pharmaceuticals
Medicine & Pharmaceuticals News Releases via PRNewswire
Film & Motion Picture News Releases via PRNewswire
Film & Motion Picture
Film & Motion Picture News Releases via PRNewswire
Economic News and Analysis
Economic News Releases via PRNewswire
Computer Software
Computer Software News Releases via PRNewswire
Computer Networks
Computer Networks News Releases via PRNewswire
Computer Hardware
Computer Hardware News Releases via PRNewswire
Biotech News Releases via PRNewswire
Biotechnology
Biotechnology News Releases via PRNewswire

Medicine & Pharmaceuticals - Wandtv.com, NewsCenter17, StormCenter17, Central Illinois News-

Medicine & Pharmaceuticals News Releases via PRNewswireMore>>